Is a tumor ever too small to send off a genomic assay like Oncotype or Mammoprint in HR positive, HER2 negative stage 1 breast cancer?
Community PollStarted
Do you routinely perform predictive genomic assays for low risk tumors (HR positive, Her2 negative, Grade 1 without LVI) even when its a T1b lesion?
72 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on · Updated on
The Oncotype DX has been used to identify high risk stage T1b tumors that may benefit from the addition of chemotherapy such as Taxotere/Cytoxan for 4 cycles and has been part of NCCN guidelines for quite some time. We do consider chemotherapy for high risk T1b luminal B tumors (either on basis of h...
Join for free or sign in to see the full answer